Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: an internal examination of venture capital

This article was originally published in Scrip

Executive Summary

These are comparatively uncomfortable times for life science venture capital (VC) investors. In the 1990s, VCs could bring a life science company to the public markets, recover their cost by divesting part of their investment at the IPO, and see their remaining holding rocket in value as generalist shareholders clamoured for the next hot biotech biotechnology IPO. A few months after the IPO, and with a little luck, many companies were also able to complete secondary offerings of stock from their VCs, CEOs and CFOs, putting most of the company’s shares in public hands.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel